The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.
Read MoreExplore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.
Daniel BuchenbergerThe Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.
Emma BijesseWelcome to the August 2024 edition of our Monthly Insight Series! This month we are combining insights from 3 of our customer segment reports and reflecting on provider and payer relationships.
Emma BijesseThe ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.
Emma Bijesse, Daniel BuchenbergerWelcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.
Chris Van DenburgWelcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.
Ashutosh ShethWhile provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.
Cindy ChenWelcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.
Emma BijesseWelcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.
Lee BlansettNavigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.
Emma BijesseWelcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.
Welcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.
Lee BlansettWelcome to the January 2024 edition of our Monthly Insight Series. This month we are discussing clinical decision support systems in oncology.
Chris Van DenburgWelcome to the December 2023 edition of our Monthly Insight Series. This month we are discussing standout quotes from discussions we had this year, and how they impact our key customer segments.
Chris Van Denburg, Cindy ChenWelcome to the November 2023 edition of our Monthly Insight Series. This month we are highlighting a few key findings from our recently published report on Oncology Clinical Pathways.
Lee BlansettWelcome to the October 2023 edition of our Monthly Insight Series. This month we highlight a specific finding from our 2023 Payer Annual Oncology Trend Report that was just released in September: Payers’ top cancer cost targets.
Chris Van DenburgWelcome to the September 2023 edition of our Monthly Insight Series. This month we are giving a quick overview of the various reports we’ve released to our clients this summer—it’s been a busy one!
Welcome to the August 2023 edition of our Monthly Insight Series. This month we take a deeper look into independent community oncology practices’ evolving interest in joining oncology network aggregators.
CMMI has launched its new oncology pilot, the Enhancing Oncology Model, sparking questions about its new features vs the Oncology Care Model, the benefits and concerns for participating practices, and CMMI’s ability to successfully implement the program.
Welcome to the July 2023 edition of our Monthly Insights Series. This month we want to share some more thoughts on opportunities for manufacturer engagement with IDN stakeholders—the IDN pharmacy/pharmacists, in particular.
Cindy ChenAs more providers explore clinical pathways as a tool for increasing clinical consistency and quality, we need to examine adoption benefits and challenges, provider compliance, and potential access risks for manufacturers.
Lee BlansettWelcome to the May 2023 edition of our Monthly Insight Series. This month we are examining how Payers’ oncology pathways sometimes conflict with their own coverage policies, and how they can differ but still be aligned from a Payer perspective.
Chris Van DenburgChanges to Medicare, including Medicare Advantage, have important repercussions on patient access to care, oncologists’ treatment decisions, and drug manufacturers’ processes.
Lee BlansettWelcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.
Cindy ChenWelcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.
Chris Van DenburgWe want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.
Lee BlansettWelcome to the February 2023 edition of our Monthly Insight Series. This month we discuss how community oncology providers are engaging in value-based care.
Lee BlansettWelcome to the January 2023 edition of our Monthly Insight Series. This month we discuss value-based care in oncology from a private-payer perspective.
Chris Van Denburg, Lee BlansettWelcome to the December 2022 edition of our Monthly Insight Series. This month we highlight the Inflation Reduction Act of 2022 (IRA).
Cindy Chen, Lee BlansettWelcome to the October 2022 edition of our Monthly Insight Series. This month we discuss our new Perspectives on Vertical Payers report.
Chris Van Denburg